BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerativ

Event · Earnings
Original reporting
Published Aug 14, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BCLI
Neutral
medium confidence
Mentioned
$BCLI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BCLINeutralMed
01

Why it matters

Traders can update models for cash burn and operating expense trajectory, while also repricing regulatory and operational progress toward the Phase 3b ENDURANCE trial under an FDA SPA.

02

Market read

Fresh Q2 financials show reduced cash and higher net loss, while the company highlights FDA SPA-backed readiness for a Phase 3b ALS trial, creating a mixed catalyst set.

03

What to watch

Cash and restricted cash are low versus prior year, while current liabilities and short-term loans remain sizable, increasing sensitivity to additional financings before trial start.

Relevance 7/10Novelty 7/10Timing: filed after-hours Aug 14, 2026, for Q2 results and corporate update

Background

The SEC 8-K (Item 2.02) reports BrainStorm Cell Therapeutics Q2 2026 results and a corporate update focused on NurOwn for ALS and leadership/financing actions.

Company-level read

Ticker impact

$BCLINeutralMedium confidence
Context

BCLI disclosed Q2 2026 financials and said it is completing preparations to initiate the Phase 3b ENDURANCE NurOwn study under an FDA SPA.

Expected impact

Likely modest, two-sided reaction: financing/cash concerns may cap upside, while FDA SPA readiness can support sentiment.

Evidence & confidence

The filing provides fresh balance-sheet and P&L datapoints (cash down, higher G&A, larger net loss) plus a concrete clinical/regulatory readiness update (planned enrollment, SPA with FDA).

Market effects

Adds another data point on how ALS cell-therapy sponsors are using FDA Special Protocol Assessments to de-risk late-stage trial design.

No clear regional spillover beyond US biotech/OTCQB sentiment.

Limited, as the disclosure is US regulatory and company-specific.

Counterpoint

The Phase 3b readiness narrative may not translate into near-term enrollment or cash runway, so dilution risk could dominate the stock reaction.

Key entities

  • BrainStorm Cell Therapeutics Inc.

    OTCQB-listed adult stem cell therapeutics developer; subject of the 8-K with Q2 2026 financials and NurOwn Phase 3b ENDURANCE update.

  • NurOwn (MSC-NTF)

    Autologous MSC-derived cell therapy for ALS; company states preparations to initiate Phase 3b ENDURANCE under an FDA Special Protocol Assessment.

  • Peter J. Pitts

    Appointed Executive Chairman and Chief Strategic Regulatory and Policy Officer to lead regulatory, operational, partnership, and capital-markets initiatives.

Related articles

$BCLIMed

BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Notice of Pendency and Proposed Settlement of Stockholder

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE BRAINSTORM CELL Lead Case No. 1:24-cv-01095-DEH THERAPEUTICS, INC. DERIVATIVE LITIGATION EXHIBIT C NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS TO: ALL RECORD HOLDERS AND

$BCLIMed

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, November 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegener

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

$SUNEMed

SUNATION ENERGY ANNOUNCES THIRD QUARTER 2026 RESULTS; REPORTS SEQUENTIAL REVENUE AND GROSS MARGIN IMPROVEMENT AND PROVIDES SUNIVA MERGER UPDATE

SUNation Energy, Inc. (SUNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SUNATION ENERGY ANNOUNCES THIRD QUARTER 2026 RESULTS; REPORTS SEQUENTIAL REVENUE AND GROSS MARGIN IMPROVEMENT AND PROVIDES SUNIVA MERGER UPDATE Third-quarter revenue of $11.2 million increased from $8.2 million in the second quarter; year-over-year results continued

$TRUGMed

TruGolf Reports Top Third Quarter Results

TruGolf Holdings, Inc. (TRUG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TruGolf Reports Top Third Quarter Results Third Quarter Revenue Up 29.4% Year-over-Year to $5.3 Million Salt Lake City, Utah, November 16, 2026 - TruGolf Holdings, Inc. (NASDAQ: TRUG), the owner of TruGolf, a leading provider of golf simulator software and hardware,